{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:05Z","timestamp":1791304325607,"version":"4.3.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"am","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.annder.2022.11.013","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T16:11:51Z","timestamp":1692029511000},"page":"208-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice"],"prefix":"10.1016","volume":"150","author":[{"given":"V.","family":"Sibaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sollena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2022.11.013_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2022.11.013_b0010","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2022.11.013_b0015","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2022.11.013_b0020","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2022.11.013_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13691","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2022.11.013_b0030","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1002\/onco.13684","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: updated analysis with up to 5 years of follow-up","volume":"26","author":"Finn","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2022.11.013_b0035","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","article-title":"Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review","volume":"44","author":"Silvestri","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.annder.2022.11.013_b0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40257-021-00645-0","article-title":"Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system","volume":"23","author":"Raschi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.annder.2022.11.013_b0045","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-021-06169-9","article-title":"Cutaneous toxicities occurring during palbociclib (CDK4\/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience","volume":"188","author":"Chawla","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annder.2022.11.013_b0050","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jaad.2021.04.092","article-title":"Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase 4\/6 inhibitor use","volume":"86","author":"Amigo","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2022.11.013_b0055","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/tbj.13570","article-title":"Toxic epidermal necrolysis associated with ribociclib in a patient with metastatic breast cancer","volume":"26","author":"Bozkaya","year":"2020","journal-title":"Breast J"},{"key":"10.1016\/j.annder.2022.11.013_b0060","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.1111\/ajd.13608","article-title":"Acute generalised exanthematous pustulosis after initiation of palbociclib therapy for metastatic breast cancer","volume":"62","author":"Gambichler","year":"2021","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.annder.2022.11.013_b0065","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4048\/jbc.2019.22.e44","article-title":"Ribociclib-related Stevens-Johnson syndrome: oncologic awareness, case report, and literature review","volume":"22","author":"L\u00f3pez-G\u00f3mez","year":"2019","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.annder.2022.11.013_b0070","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jdcr.2017.12.015","article-title":"Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer","volume":"4","author":"Karagounis","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2022.11.013_b0075","first-page":"e10229","article-title":"Bullous skin rash: a rare case of palbociclib-induced dermatological toxicity","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.annder.2022.11.013_b0080","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cup.13673","article-title":"Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: a case report and literature review","volume":"47","author":"Russell-Goldman","year":"2020","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2022.11.013_b0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jdcr.2021.05.028","article-title":"Subacute cutaneous lupus erythematosus following abemaciclib therapy for metastatic breast cancer","volume":"14","author":"Kurtyka","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2022.11.013_b0090","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1111\/ijd.14716","article-title":"Chronic cutaneous lupus erythematosus (discoid lupus) induced by palbociclib","volume":"59","author":"Freedman","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2022.11.013_b0095","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/cup.13696","article-title":"A case of discoid lupus erythematosus because of palbociclib","volume":"47","author":"Calabrese","year":"2020","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2022.11.013_b0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10549-020-05914-w","article-title":"Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors","volume":"185","author":"Sollena","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annder.2022.11.013_b0105","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/14737140.2017.1355242","article-title":"Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis","volume":"17","author":"Lasheen","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.annder.2022.11.013_b0110","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/0284186X.2020.1738547","article-title":"The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4\/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)","volume":"59","author":"Eiger","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.annder.2022.11.013_b0115","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","article-title":"Endocrine therapy-induced alopecia in patients with breast cancer","volume":"154","author":"Freites-Martinez","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2022.11.013_b0120","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.21037\/apm-21-1156","article-title":"Oral adverse effects of CDK4\/6 inhibitors among breast cancer patients: a systematic review and meta-analysis","volume":"10","author":"Long","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.annder.2022.11.013_b0125","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.rpor.2019.03.001","article-title":"Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: a case report","volume":"24","author":"Messer","year":"2019","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.annder.2022.11.013_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.643155","article-title":"Role of the combination of cyclin-dependent kinase inhibitors (CDKI) and radiotherapy (RT) in the treatment of metastatic breast cancer (MBC): advantages and risks in clinical practice","volume":"11","author":"Gagliano","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.annder.2022.11.013_b0135","first-page":"79","article-title":"CDK 4\/6 inhibitors combined with radiotherapy: a review of literature","volume":"26","author":"Bosacki","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.annder.2022.11.013_b0140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.hemonc.2020.04.005","article-title":"Ribociclib-induced radiation recall dermatitis following stereotactic body radiation therapy: case report and literature review","volume":"14","author":"Erjan","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.annder.2022.11.013_b0145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4048\/jbc.2021.24.e1","article-title":"Ribociclib-induced erythema dyschromicum perstans (Ashy Dermatosis)-like pigmentation in a metastatic breast cancer patient","volume":"24","author":"Mariano","year":"2021","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.annder.2022.11.013_b0150","doi-asserted-by":"crossref","first-page":"e755","DOI":"10.1016\/j.clbc.2018.07.006","article-title":"Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by palbociclib in a metastatic breast cancer patient: a case report","volume":"18","author":"Guillemois","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.annder.2022.11.013_b0155","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.breast.2020.05.011","article-title":"Henoch-sch\u00f6nlein Purpura (HSP) in a patient on Abemaciclib","volume":"52","author":"Omarini","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.annder.2022.11.013_b0160","first-page":"12","article-title":"Palbociclib-induced IgA vasculitis","volume":"27","author":"Patel","year":"2021","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2022.11.013_b0165","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/ced.14361","article-title":"Palbociclib-induced histiocytoid Sweet syndrome","volume":"46","author":"Fust\u00e0-Novell","year":"2021","journal-title":"Clin Exp Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963823000479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963823000479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:11:14Z","timestamp":1758971474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963823000479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0151963823000479"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2022.11.013","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2022.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}